Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Water Infusion first Clear all
Completed Phase 2 Interventional Results available

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

NCT01185171
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
ZD 1839 500mg
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Sep 21, 2026, 2:41 PM EDT
Terminated Phase 2 Interventional Results available

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

NCT05113966
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Trilaciclib, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Chandler, Arizona • Bakersfield, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 21, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT01453205
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
MEDI-551 2 mg/kg, Rituximab, ICE, DHAP, Autologous Stem Cell Transplant (ASCT), MEDI-551 4 mg/kg
Drug · Procedure
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Burbank, California • Palm Springs, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 21, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

NCT01847001
View directory record Official record
Conditions
Locally Advanced Malignant Neoplasm, Breast Cancer
Interventions
Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim
Drug · Other · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Sep 21, 2026, 2:41 PM EDT
Completed Phase 2 Interventional

Investigation of Sleep in the Intensive Care Unit

NCT03355053
View directory record Official record
Conditions
Delirium, Sleep
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 21, 2026, 2:41 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Iadademstat + SBRT With Atezo in ES-SCLC

NCT07113691
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions
Iadademstat, Atezolizumab, SBRT
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 21, 2026, 2:41 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure

NCT01092325
View directory record Official record
Conditions
Heart Failure
Interventions
CXL-1020, Placebo for CXL-1020 Cohort 1, Placebo for CXL-1020 Cohort 2, CXL-1020 Dose for Echo Cohort A, CXL-1020 Doses for Echo Cohort B
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Sep 21, 2026, 2:41 PM EDT
Recruiting Not applicable Interventional

Effect of Giving Reduced Fluid in Children After Trauma

NCT04201704
View directory record Official record
Conditions
Critical Illness, Pediatrics, General Surgery, Fluid Therapy, Wounds and Injuries
Interventions
Balanced crystalloid solution volume administration, Packed Erythrocytes Units, Blood Product Unit volume, Plasma volume, Platelets volume
Other
Lead sponsor
Columbia University
Other
Eligibility
6 Months to 15 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Buffalo, New York • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 21, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn

NCT00243243
View directory record Official record
Conditions
Burns
Interventions
Recombinant Factor VIIa, Placebo
Drug
Lead sponsor
United States Army Institute of Surgical Research
Federal
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Sep 21, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT04644237
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Aurora, Colorado • Orlando, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 21, 2026, 2:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

MIRA CONNECT Study

NCT06802263
View directory record Official record
Conditions
Pregnancy of Unknown Location (PUL)
Interventions
at-home quantitative urine b-hCG test
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 21, 2026, 2:41 PM EDT
Recruiting Phase 1 Interventional

Effect of Insulin Lowering on Lipogenesis

NCT07403604
View directory record Official record
Conditions
Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST)
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 21, 2026, 2:41 PM EDT
Terminated Phase 1 Interventional

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT02277184
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT)
Drug · Radiation
Lead sponsor
Julie E. Bauman, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 21, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

NCT03623373
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Bendamustine, Rituximab, Acalabrutinib, Cytarabine, Leukapheresis, Peripheral blood, Oral rinse, Bone marrow collection
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 21, 2026, 2:41 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

NCT07810946
View directory record Official record
Conditions
Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions
Sodium Acetate, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 21, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

ATG-GCSF in New Onset Type 1 Diabetes

NCT02215200
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
13
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 21, 2026, 2:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma

NCT00634751
View directory record Official record
Conditions
Pancreatic Neoplasms, Bile Duct Neoplasms
Interventions
Oxaliplatin, Capecitabine, Sorafenib
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 21, 2026, 2:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

NCT02963831
View directory record Official record
Conditions
Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
Interventions
ONCOS-102, Durvalumab, Cyclophosphamide
Biological · Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
San Diego, California • Miami, Florida • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 21, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

NCT04634539
View directory record Official record
Conditions
Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Gemcitabine, Nab-paclitaxel, L-glutamine
Drug
Lead sponsor
Jun Gong, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Beverly Hills, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 21, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures

NCT00618098
View directory record Official record
Conditions
Reversal of Anticoagulant Treatment
Interventions
Octaplex (human prothrombin complex concentrate), Fresh frozen plasma
Biological
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 21, 2026, 2:41 PM EDT
Completed Phase 4 Interventional Results available

Treating Phantom Limb Pain Using Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study

NCT01824082
View directory record Official record
Conditions
Phantom Limb Pain
Interventions
Perineural infusion [continuous peripheral nerve block(s)]
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Palo Alto, California • San Diego, California • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 21, 2026, 2:41 PM EDT
Completed Not applicable Interventional Results available

Physiologic Response to Glucagon at Varying Insulin Levels

NCT01483651
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Glucagon, Insulin
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Sep 21, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

NCT02216084
View directory record Official record
Conditions
Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
Recombinant ADAMTS13
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
12 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Dublin, Ohio • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 21, 2026, 2:41 PM EDT
Terminated Phase 2 Interventional Results available

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

NCT04323436
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Spartalizumab, Capmatinib, spartalizumab placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 21, 2026, 2:41 PM EDT